Felice Verduyn—van Weegen has been a member of our board of directors since October 2023. Ms. Verduyn—van Weegen has been a Partner at EQT Life Sciences, or EQT, a healthcare investment company, since July 2022. Ms. Verduyn—van Weegen worked for EQT’s predecessor, LSP Advisory B.V., or LSP, from March 2015 until July 2022. Prior to joining LSP, Ms. Verduyn—van Weegen worked as a consultant at McKinsey & Company in Amsterdam, Netherlands. Prior to McKinsey, Ms. Verduyn—van Weegen was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, Massachusetts. Ms. Verduyn—van Weegen serves and has served on several company boards, including Amolyt Pharma, a clinical-stage endocrine company which was sold to AstraZeneca in 2024, from July 2019 to July 2024, and Evommune, Inc. (NYSE: EVMN), a clinical-stage immunology company, since September 2021. Ms. Verduyn—van Weegen holds a MSc degree (cum laude) in Neuroscience from VU University Amsterdam and an MBA degree (with distinction) from Columbia Business School in New York. We believe Ms. Verduyn is qualified to serve on our board of directors because of her extensive experience in healthcare investments and her board service.